+ Translate

Oxandrolone in AIDS-wasting myopathy

, : Oxandrolone in AIDS-wasting myopathy. Aids 10(14): 1657-1662

Objective: To evaluate oxandrolone, an oral anabolic steroid with potent anabolic activity and minimal androgenic effects, for the treatment of AIDS-associated myopathy and wasting. Methods: In a multicenter, double-blind study, 63 HIV-seropositive men with gt 10% loss of body weight were randomized to receive either placebo, 5 mg/day oxandrolone, or 15 mg/day oxandrolone for 16 weeks. Body weight, neuromuscular evaluation, and measures of well-being were repeatedly assessed. Results: Patients who received 15 mg/day oxandrolone showed weight gain throughout the 16-week treatment period. Overall, the 5 mg/day oxandrolone group maintained their weight gain over the 16-week period, whereas the placebo group showed continual weight loss. At week 16, significantly more patients in the 15 mg/day dose group reported increases in appetite and activity than those receiving placebo. There were no consistent, dose-related, statistically significant differences from baseline in laboratory values or adverse events. Conclusion: Oxandrolone, at a dose of either 5 mg/day or 15 mg/day, in contrast to placebo, had a positive impact on the weight and well-being of HIV-seropositive patients suffering from wasting and weakness. Measurable improvement in muscle strength was not noted at the doses employed in this study. Oxandrolone was well tolerated in all the patients who were enrolled in the study. Based on the results reported here, additional studies using higher doses of oxandrolone seem warranted.

(PDF same-day service: $19.90)

Accession: 002914049

PMID: 8970686

DOI: 10.1097/00002030-199612000-00010

Submit PDF Full Text: Here

Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:

Related references

Poles, M.A.; Lin, A.; Weiss, W.R.; Gocke, M.; Dieterich, D.T., 1997: Oxandrolone as a treatment for aids-related weight loss and wasting. Gastroenterology 112(4 SUPPL ): A1062

Butcher, D.; Faith, T.; Thompson, D.; Lapins, D.; Hamel, E., 2000: Effects of oxandrolone on body weight and composition in patients with AIDS wasting. AIDS (Hagerstown) 14(Supplement 4): S60, October

Simpson D.M.; Bender A.N.; Farraye J.; Wolfe D.E., 1989: Aids wasting syndrome a treatable myopathy. Neurology 39(3 SUPPL 1): 152

Taiwo, B.O., 2000: HIV-associated wasting: brief review and discussion of the impact of oxandrolone. This is a brief review of human immunodeficiency virus (HIV)-associated wasting with expanded discussion of one treatment agent, oxandrolone. HIV-associated wasting is the involuntary loss of more than 10% of baseline body weight in the presence o...

James, J.S., 1995: Wasting syndrome: oral oxandrolone re-released in U.S. More than thirty years ago, the Food and Drug Administration (FDA) approved the oral anabolic steroid oxandrolone (brand name Oxandrin) for regaining weight lost from infectious diseases. Companies in the United States have not manufactured it bec...

Orr, R.; Fiatarone Singh, M., 2004: The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. There has been increasing interest in the development of effective agents that can be safely used to promote anabolism in the clinical setting for patients with chronic wasting conditions as well as in the prevention and treatment of frailty assoc...

Segal, D.M.; Perez, M.; Shapshak, P., 1999: Oxandrolone, used for treatment of wasting disease in HIV-1-infected patients, does not diminish the antiviral activity of deoxynucleoside analogues in lymphocyte and macrophage cell cultures. Antiviral agents are the primary therapy for patients infected with HIV-1. However, supportive therapies are often necessary in addition to antiviral drugs because of the devastating wasting process associated with HIV-1 infection and AIDS. Oxandr...

Mora Rodriguez, G.; Feregrino Goyos, M.; Gomez Caro, W.H.; Eid Lidt, G.; Alvarado Diez, R.; Gallegos Perez, H., 1996: When why and whom enteral nutritional support in AIDS wasting syndrome of AIDS and in the early HIV disease. ELEVENTH INTERNATIONAL CONFERENCE ON AIDS [Author] Eleventh International Conference on AIDS, Vol One One world: One hope : 308

Berger, J.R.; Pall, L.; Winfield, D., 1993: Effect of anabolic steroids on HIV-related wasting myopathy. Human immunodeficiency virus type 1 (HIV-1) is frequently associated with weakness and muscle wasting, referred to as HIV-1 wasting myopathy. This illness, often observed in the advanced stages of acquired immunodeficiency syndrome (AIDS), respond...

Hammond Tooke, G.; Clark, M.; Taylor, P.; Pollock, M., 1997: Nemaline myopathy with forearm wasting and neurogenic changes on electromyography. Journal of the Neurological Sciences 150(SUPPL ): S122